Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)

#1524

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.

Aim(s): To study mTOR pathway activation as a new discriminator for EVE therapy.

Materials and methods: FFPE tumor material of 60 pNEN patients from 4 centers was macrodissected and RNA was extracted. Upregulation of 12 mTOR pathway signaling members was studied by TaqMan based RT-qPCR assays. Relative gene expression was determined according to the 40-DCT method using CALM2 as housekeeping gene.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lock A

Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,

Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,